Summary
Angiotensin Ii has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Lupus Nephritis would be drug repurposing rather than first-in-human development. This does not mean it is approved for Lupus Nephritis. ClinicalTrials.gov lists 1 registered trial linking Angiotensin Ii to Lupus Nephritis: 1 is terminated, withdrawn, suspended or of unknown status. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registered activity dates to 2017. No published literature item is linked to Angiotensin Ii and Lupus Nephritis in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Lupus Nephritis ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous remission essentially zero in class III/IV LN; progression to ESRD in 10-20% at 10 years on standard therapy; renal flares in 30-50% of patients achieving initial response.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 21.0 (trials 1.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 1 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 1 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | agonist |
| Data sources | DGIdb |
| Linked via biomarker / target | AGTR1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT03526042 | Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis 2017 | status unknown | Not applicable | 40 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: agonist.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Angiotensin Ii approved for Lupus Nephritis?
Angiotensin Ii has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Lupus Nephritis would be drug repurposing rather than first-in-human development. This does not mean it is approved for Lupus Nephritis. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Angiotensin Ii in clinical trials for Lupus Nephritis?
ClinicalTrials.gov lists 1 registered trial linking Angiotensin Ii to Lupus Nephritis: 1 is terminated, withdrawn, suspended or of unknown status. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registered activity dates to 2017.
What does the evidence show for Angiotensin Ii in Lupus Nephritis?
Trials of Angiotensin Ii in Lupus Nephritis are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.